Eversept Partners LP Trims Stake in Assembly Biosciences, Inc. $ASMB

Eversept Partners LP lowered its position in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 74.4% during the 1st quarter, HoldingsChannel reports. The firm owned 40,889 shares of the biopharmaceutical company’s stock after selling 118,787 shares during the period. Eversept Partners LP’s holdings in Assembly Biosciences were worth $1,135,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Informed Momentum Co LLC boosted its stake in Assembly Biosciences by 1.6% during the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after buying an additional 451 shares during the period. ADAR1 Capital Management LLC increased its stake in Assembly Biosciences by 4.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after acquiring an additional 800 shares during the last quarter. Geode Capital Management LLC increased its stake in Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock worth $4,468,000 after acquiring an additional 1,212 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after acquiring an additional 1,634 shares in the last quarter. Finally, Palumbo Wealth Management LLC raised its holdings in shares of Assembly Biosciences by 7.2% in the 4th quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 2,507 shares in the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Trading Up 1.4%

NASDAQ ASMB opened at $25.91 on Tuesday. The firm has a market cap of $411.71 million, a PE ratio of -235.52 and a beta of 1.08. Assembly Biosciences, Inc. has a 1-year low of $16.90 and a 1-year high of $39.71. The stock has a 50-day moving average of $25.95 and a 200-day moving average of $27.64.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. The business had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. As a group, equities research analysts forecast that Assembly Biosciences, Inc. will post 1.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Finally, Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.